SS
PTGX icon

Simplicity Solutions’s Protagonist Therapeutics PTGX Stock Holding History

Simplicity Solutions’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,411
Closed -$174K – 1094
2023
Q3 		$174K Buy
+10,411
New +$202K 0.01% 915

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Simplicity Solutions's PTGX Position: Q4 2023 in Review

Simplicity Solutions sold out of Protagonist Therapeutics (PTGX) in Q4 2023, closing a stake of 10,411 shares — an estimated $174K sold.

Simplicity Solutions first reported a position in PTGX in Q3 2023 and held it in 1 quarter. The position peaked at $174K in Q3 2023. 156 funds tracked by Wall St. Rank hold PTGX as of Q4 2023.

  • Simplicity Solutions reported no remaining Protagonist Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Simplicity Solutions sold 10,411 Protagonist Therapeutics shares in Q4 2023, an estimated $174K.
  • Simplicity Solutions first reported a position in Protagonist Therapeutics in Q3 2023 and held it in 1 quarter.
  • Simplicity Solutions's Protagonist Therapeutics position peaked at $174K in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2023.

Based on Simplicity Solutions's 13F filing for Q4 2023, filed 29 Jan 2024.